Patients and physicians work together during the diagnosis, treatment, and follow-up process to focus on changes in serum prostate-specific antigen (PSA) values on labs (laboratory and pathological examinations) and to obtain Gleason score results for pathological diagnosis. The clinical assessment of the prognostic risk (i.e. risk factors for local recurrence and clinical progression after treatment) degree of prostate cancer is mainly based on serum PSA level, Gleason score level and clinical stage; it can be divided into three levels i.e. low risk, intermediate risk and high risk; the scope of assessment is early and intermediate stage prostate cancer, which is an important reference value for guiding clinical treatment. Low-risk prostate cancer: PSA ≤ 10ug/L; Gleason score ≤ 6; clinical stage ≤ T2a, usually found incidentally, such as surgery for prostate enlargement. Low-risk patients, mainly early stage limited prostate cancer, can be treated relatively conservatively, such as “watch and wait” or, for patients who are concerned about “delaying treatment”, minimally invasive, i.e., focal cryotherapy can be used. Intermediate risk prostate cancer: PSA 10-20ug/L; Gleason score 7; clinical stage T2b; Gleason score 7. Of course, there are less consistent cases, for example, last night I obtained a patient consultation information: “Gleason score 7, but PSA 268ug/L”. Although there are no clinical staging results, I assume that this is a hypofractionated tumor (more malignant) and may be difficult to include in the early stage category. The standard treatment for intermediate-risk limited prostate cancer is “open surgery”, radiation therapy, and cryotherapy. High-risk prostate cancer: PSA >20ug/L; Gleason score ≥8; clinical stage ≥T2c; Gleason score ≥8. Patients with high-risk limited prostate cancer face high risk factors for tumor progression after treatment when choosing “open surgery” or radiotherapy or cryotherapy, and therefore require combined neoadjuvant or adjuvant “endocrine therapy”. Accordingly, patients can self-judge the level of prognostic risk based on serum PSA level, Gleason score and clinical stage, and choose the appropriate treatment according to the doctor’s advice, and it is helpful to self-monitor after treatment. At the same time, it also facilitates doctor-patient communication and exchange.